Konstantinos Mantsopoulos1, Heinrich Iro2. 1. Hals-Nasen-Ohren-Klinik, Kopf- und Halschirurgie, Universitätsklinikum Erlangen-Nürnberg, Waldstr. 1, 91054, Erlangen, Deutschland. konstantinos.mantsopoulos@uk-erlangen.de. 2. Hals-Nasen-Ohren-Klinik, Kopf- und Halschirurgie, Universitätsklinikum Erlangen-Nürnberg, Waldstr. 1, 91054, Erlangen, Deutschland.
Abstract
BACKGROUND: Due to the rarity of primary parotid malignancies, there are currently only limited clinical study data on the optimal surgical therapy. Parotid malignancies encompass a broad spectrum of more than 20 different histological subtypes with varying biology, which thus represents a challenge for even experienced pathologists and head and neck surgeons with proven expertise in salivary gland surgery. OBJECTIVE: The aim of this review article is to provide an overview of the current literature on surgical therapy of the primary tumor and the cN0 neck as well as treatment of the facial nerve, and to shed light on the various controversial aspects of this topic. RESULTS: In salivary gland oncology there is a trend towards safe (R0) but more conservative surgery. Currently, less-invasive surgical approaches could potentially be applied in a small subgroup with carefully selected caudally located and R0-resected "low-grade tumors" in stages T1-T2 and cN0 in relatively young patients with high compliance and more in the context of structured clinical studies. Elective neck dissection in the case of cN0 status should be carried out if risk factors for occult cervical lymph node metastasis (T3-T4a, "high-grade subtypes," advanced age, lymphangitic carcinomatosis) are present. In cases of small "low-grade parotid carcinomas," narrow resection margins or even microscopic tumor residues on the facial nerve can potentially be adequately compensated with adjuvant radiation therapy. However, due to the lack of solid data, the significance of the actual effect of the radiation in this situation should be viewed with great caution.
BACKGROUND: Due to the rarity of primary parotid malignancies, there are currently only limited clinical study data on the optimal surgical therapy. Parotid malignancies encompass a broad spectrum of more than 20 different histological subtypes with varying biology, which thus represents a challenge for even experienced pathologists and head and neck surgeons with proven expertise in salivary gland surgery. OBJECTIVE: The aim of this review article is to provide an overview of the current literature on surgical therapy of the primary tumor and the cN0 neck as well as treatment of the facial nerve, and to shed light on the various controversial aspects of this topic. RESULTS: In salivary gland oncology there is a trend towards safe (R0) but more conservative surgery. Currently, less-invasive surgical approaches could potentially be applied in a small subgroup with carefully selected caudally located and R0-resected "low-grade tumors" in stages T1-T2 and cN0 in relatively young patients with high compliance and more in the context of structured clinical studies. Elective neck dissection in the case of cN0 status should be carried out if risk factors for occult cervical lymph node metastasis (T3-T4a, "high-grade subtypes," advanced age, lymphangitic carcinomatosis) are present. In cases of small "low-grade parotid carcinomas," narrow resection margins or even microscopic tumor residues on the facial nerve can potentially be adequately compensated with adjuvant radiation therapy. However, due to the lack of solid data, the significance of the actual effect of the radiation in this situation should be viewed with great caution.
Authors: Allen M Chen; Phillip J Granchi; Joaquin Garcia; M Kara Bucci; Karen K Fu; David W Eisele Journal: Int J Radiat Oncol Biol Phys Date: 2007-01-22 Impact factor: 7.038
Authors: Daniele Borsetto; Oreste Iocca; Armando De Virgilio; Paolo Boscolo-Rizzo; Veronica Phillips; Piero Nicolai; Giuseppe Spriano; Jonathan Fussey; Pasquale Di Maio Journal: J Oral Pathol Med Date: 2020-12-26 Impact factor: 4.253
Authors: Andrés Coca-Pelaz; Juan P Rodrigo; Patrick J Bradley; Vincent Vander Poorten; Asterios Triantafyllou; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Missak Haigentz; Robert P Takes; Vanni Mondin; Afshin Teymoortash; Lester D R Thompson; Alfio Ferlito Journal: Oral Oncol Date: 2015-05-02 Impact factor: 5.337
Authors: Safina Ali; Frank L Palmer; Monica DiLorenzo; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Ann Surg Oncol Date: 2014-04-10 Impact factor: 5.344
Authors: José F Carrillo; Rafael Vázquez; Margarita C Ramírez-Ortega; Ana Cano; Francisco J Ochoa-Carrillo; Luis F Oñate-Ocaña Journal: Cancer Date: 2007-05-15 Impact factor: 6.860
Authors: Tobias Ettl; Martin Gosau; Gero Brockhoff; Stephan Schwarz-Furlan; Abbas Agaimy; Torsten E Reichert; Christian Rohrmeier; Johannes Zenk; Heinrich Iro Journal: Head Neck Date: 2013-06-18 Impact factor: 3.147